Quince Therapeutics, Inc. (QNCX) - Net Assets
Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has net assets worth $15.67 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($26.62 Million) and total liabilities ($10.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Quince Therapeutics, Inc. (QNCX) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.67 Million |
| % of Total Assets | 58.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | -130.12% |
| 10-Year Change | N/A |
| Growth Volatility | 85.98 |
Quince Therapeutics, Inc. - Net Assets Trend (2017–2025)
This chart illustrates how Quince Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. See QNCX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Quince Therapeutics, Inc. (2017–2025)
The table below shows the annual net assets of Quince Therapeutics, Inc. from 2017 to 2025. For live valuation and market cap data, see market cap of Quince Therapeutics, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-35.71 Million | -218.47% |
| 2024-12-31 | $30.15 Million | -64.57% |
| 2023-12-31 | $85.08 Million | -15.42% |
| 2022-12-31 | $100.59 Million | -15.17% |
| 2021-12-31 | $118.59 Million | -31.16% |
| 2020-12-31 | $172.26 Million | +49.17% |
| 2019-12-31 | $115.48 Million | +61.69% |
| 2018-12-31 | $71.42 Million | +452.17% |
| 2017-12-31 | $-20.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Quince Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44010200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $55.00K | % |
| Other Comprehensive Income | $5.75 Million | % |
| Other Components | $418.93 Million | % |
| Total Equity | $-35.71 Million | 100.00% |
Quince Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Quince Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Austin Gold Corp
NYSE MKT:AUST
|
$17.66 Million |
|
GR.SOU.COP. LS-01
F:E9E
|
$17.67 Million |
|
Rackla Metals Inc
V:RAK
|
$17.68 Million |
|
Monami
KO:005360
|
$17.70 Million |
|
Reko International Group Inc
V:REKO
|
$17.65 Million |
|
SenzaGen AB
ST:SENZA
|
$17.65 Million |
|
IVP Limited
NSE:IVP
|
$17.65 Million |
|
LL Lucky Games publ AB
ST:LADYLU
|
$17.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Quince Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 30,146,000 to -35,714,000, a change of -65,860,000 (-218.5%).
- Net loss of 83,979,000 reduced equity.
- New share issuances of 17,689,000 increased equity.
- Other comprehensive income increased equity by 5,785,000.
- Other factors decreased equity by 5,355,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-83.98 Million | -235.14% |
| Share Issuances | $17.69 Million | +49.53% |
| Other Comprehensive Income | $5.79 Million | +16.2% |
| Other Changes | $-5.36 Million | -14.99% |
| Total Change | $- | -218.47% |
Book Value vs Market Value Analysis
This analysis compares Quince Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-9.41 | $0.90 | x |
| 2018-12-31 | $33.14 | $0.90 | x |
| 2019-12-31 | $60.68 | $0.90 | x |
| 2020-12-31 | $59.04 | $0.90 | x |
| 2021-12-31 | $39.90 | $0.90 | x |
| 2022-12-31 | $30.03 | $0.90 | x |
| 2023-12-31 | $22.85 | $0.90 | x |
| 2024-12-31 | $6.97 | $0.90 | x |
| 2025-12-31 | $-7.13 | $0.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Quince Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-49.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.21 Million |
| 2018 | -17.47% | 0.00% | 0.00x | 1.02x | $-19.62 Million |
| 2019 | -32.02% | 0.00% | 0.00x | 1.08x | $-48.53 Million |
| 2020 | -44.61% | 0.00% | 0.00x | 1.10x | $-94.08 Million |
| 2021 | -75.85% | 0.00% | 0.00x | 1.12x | $-101.80 Million |
| 2022 | -51.36% | 0.00% | 0.00x | 1.03x | $-61.72 Million |
| 2023 | -36.89% | 0.00% | 0.00x | 2.12x | $-39.89 Million |
| 2024 | -188.51% | 0.00% | 0.00x | 3.80x | $-59.84 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-80.41 Million |
Industry Comparison
This section compares Quince Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $15.67 Million | 0.00% | 0.70x | $17.66 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more